Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.

Published in: The Journal of dermatological treatment (2023)

Switching from baricitinib 4 mg to upadacitinib 30 mg effectively improved rash and pruritus.

Keyphrases